Application of international system for reporting serous fluid cytology (ISRSFC) in effusion samples-a prospective study in an oncology setting
Journal of the American Society of Cytopathology · 2023
DOI: 10.1016/j.jasc.2023.04.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Cytopathology, 2023. Verfasst von Ruchita Sachan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Serous fluid cytology is a cost-effective procedure that can help in the diagnosis, staging, and origin of the malignancy. Recently introduced International System for Reporting Serous Fluid Cytology (ISRSFC) standardizes the reporting of serous fluid cytology in the 5 categories: Category 1: Nondiagnostic (ND), Category 2: negative for malignancy (NFM), Category 3: atypia of undetermined significance (AUS), Category 4: suspicious for malignancy (SFM), and Category 5: malignant (MAL). Here, we present our experience adopting the ISRSFC. MATERIALS AND METHODS: We implemented ISRSFC in December of 2019 at our institute and included a cohort of 555 prospective effusion samples. The pertinent surgical pathology, radiology, and clinical follow-up were also extracted to assess the risk of malignancy (ROM) and performance parameters. RESULTS: The assessment of interobserver reliability indicated substantial concordance (κ = 0.717) between the 2 investigators for serous fluid categorization. A total of 555 effusion samples were classified as follows: ND, 14 (2.5%); NFM, 394 (71%); AUS, 12 (2.2%); SFM, 13 (2.3%); and MAL, 122 (22%). The ROM for the ND, NFM, AUS, SFM, and MAL categories was 57.1%, 9.9%, 66.7%, 66.7%, and 97.2%, respectively, in peritoneal effusions and 57.1%, 7.1%, 66.7%, 100%, 100%, respectively, in pleural effusions. The ROM for NFM and MAL was 0% and 100%, respectively, in pericardial effusion. CONCLUSIONS: Application of the proposed ISRSFC can help in achieving uniformity and reproducibility in diagnoses and also help in risk stratification in cytology. ISRSFC was successfully adopted by our cytology laboratory and clinicians, with overall diagnostic performance similar to previous studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
- Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. Electronic address: ganuragdr@gmail.com.
- Department of Radiation Oncology, Shrimant Rajmata Vijayaraje Scindia Medical College, Shivpuri, Madhya Pradesh, India.
Zitieren
APA
Sachan, R., Gupta, A., Awasthi, P. N., Singh, P., Anand, N., Chandra, S., Gaur, G., Husain, N., & Sachan, K. D. (2023). Application of international system for reporting serous fluid cytology (ISRSFC) in effusion samples-a prospective study in an oncology setting. Journal of the American Society of Cytopathology. https://doi.org/10.1016/j.jasc.2023.04.005
Vancouver
Sachan R, Gupta A, Awasthi PN, Singh P, Anand N, Chandra S, et al. Application of international system for reporting serous fluid cytology (ISRSFC) in effusion samples-a prospective study in an oncology setting. Journal of the American Society of Cytopathology. 2023. doi:10.1016/j.jasc.2023.04.005
BibTeX
@article{Sachan2023,
author = {Sachan, Ruchita and Gupta, Anurag and Awasthi, Punit Namrata and Singh, Pradyumn and Anand, Nidhi and Chandra, Subrat and Gaur, Gauri and Husain, Nuzhat and Sachan, Kumar Dheerendra},
title = {Application of international system for reporting serous fluid cytology (ISRSFC) in effusion samples-a prospective study in an oncology setting},
journal = {Journal of the American Society of Cytopathology},
year = {2023},
doi = {10.1016/j.jasc.2023.04.005}
}
EUVIMED